Paro Robots positions stuffed animal as therapeutic device
This article was originally published in The Gray Sheet
Executive Summary
Firm plans Dec. 1 launch of its Paro Therapeutic Robot following its Sept. 21 designation by FDA as a Class II medical device exempt from pre-market notification requirements. The device looks like a stuffed harp seal pup but is an "intelligent, interactive" robot covered in white synthetic fur intended for use in nursing homes, assisted living facilities, retirement communities, hospitals and schools "for the purpose of therapy," the company claims. Paro "allows the documented benefits of animal therapy to be administered to patients in environments ... where live animals present treatment or logistical difficulties," according to the firm's Web site. It uses sensors and an on-board computer to process voice recognition and imitate animal behavior, enabling it to "develop its own character," the firm says. It respond to users "as if it is alive, moving its head and legs, making sounds, and showing your preferred behavior," the firm notes. While the $6,000 device has been used in Japan and Europe since 2003, and was unveiled in the U.S. in 2008, Paro said it pursued FDA regulatory clearance to aid future reimbursement efforts
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.
EU Must Crack Down Harder On Fake Medical Devices, Says Innovator
Counterfeit copies of LifeVac Europe’s anti-choking devices have been registered on the EU’s EUDAMED database and continue to be sold on third-party platforms. Medtech Insight asked director of sales and marketing Matthew Banagan how the company deals with fake devices and what the authorities must do.